Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Optimal Management Of Immune-related Toxicities Associated With Checkpoint Inhibitors In Lung Cancer.
M. Howell, R. Lee, S. Bowyer, A. Fusi, P. Lorigan
Published 2015 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Antibodies against immune checkpoints including CTLA-4, PD-1 and PD-L1 are increasingly being used in lung cancer. They are associated with novel, immune related toxicities not previously encountered with established treatments for lung cancer including colitis, hepatitis, rashes, neuropathies and other rarer immune mediated toxicities. Although generally these are low grade, there is a potential to be life threatening if not managed promptly. Early recognition of toxicity and institution of management algorithms are key to ensuring patient safety. We review the common toxicities and provide recommendations on their management.
This paper references
A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis.
C. Gaudy-Marqueste (2013)
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC).
N. Rizvi (2014)
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
P. Queirolo (2014)
Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.
J. Brahmer (2014)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
E. Kim (2008)
Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
F. S. Hodi (2014)
A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts).
N. Rizvi (2013)
Anti-CTLA4 antibody-induced lupus nephritis.
F. Fadel (2009)
LBA43ANTITUMOR ACTIVITY OF PEMBROLIZUMAB (PEMBRO; MK-3475) AND CORRELATION WITH PROGRAMMED DEATH LIGAND 1 (PD-L1) EXPRESSION IN A POOLED ANALYSIS OF PATIENTS (PTS) WITH ADVANCED NON–SMALL CELL LUNG CARCINOMA (NSCLC)
E. Garon (2014)
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.
V. Chiarion-Sileni (2014)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
T. Lynch (2012)
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
A. Shaw (2013)
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
S. Novello (2016)
Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
L. Crinò (2010)
Nivolumab in previously untreated melanoma without BRAF mutation.
C. Robert (2015)
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Caroline J Voskens (2013)
Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
L. Chow (2013)
Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer
R. Harvey (2014)
Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy.
Katarzyna Chmiel (2011)
Clustered genomic variants specific to patients who develop immune-related colitis after ipilimumab for prediction of toxicity.
A. Tarhini (2014)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
Y. Bronstein (2011)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.
A. M. Di Giacomo (2010)
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
S. Topalian (2014)
Anti - CTLA 4 antibody - induced lupus nephri
F Fadel (2009)
Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.
D. Minor (2009)
Management of immune-related adverse events and kinetics of response with ipilimumab.
J. Weber (2012)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
J. Weber (2009)
LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY
J. Weber (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
C. Robert (2014)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
R. Rosell (2012)
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
Mitigating the toxic effects of anticancer immunotherapy
Tara C. Gangadhar (2014)
Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.
S. Bhatia (2009)
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
M. Frueh (2013)
Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.
R. Ibrahim (2011)
Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma.
D. Johnson (2015)
The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
J. Wolchok (2008)
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
M. Sørensen (2010)
Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.
S. Wilgenhof (2011)
Hair depigmentation as an indicator of durable response to CTLA-4 therapy.
A. Pavlick (2010)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
P. Attia (2005)
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
H. Kluger (2014)
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Stephanie G Downey (2007)
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
P. Ascierto (2014)
A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.
S. O'Day (2010)
This paper is referenced by
Clinical assessment of immune-related adverse events
A. Sosa (2018)
How should we diagnose and manage checkpoint inhibitor-associated colitis?
F. Khan (2018)
Nivolumab — perspectives in cancer treatment
H. Koseła (2016)
Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non–small‐cell lung cancer
D. Kim (2019)
Individualisierte Therapie des metastasierten Lungenkarzinoms
Georg Evers (2017)
Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist.
V. Furtado (2020)
Immunotherapy and targeted therapy-the new roadmap in cancer treatment.
Kamran Shahid (2019)
Comorbidities in the management of patients with lung cancer
C. Leduc (2017)
Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement
C. Sears (2019)
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
D. Oh (2017)
Induction of eEF2-specific antitumor CTL responses in vivo by vaccination with eEF2-derived 9mer-peptides.
H. Nakajima (2016)
The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer
Wenjie Guo (2017)
Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features
M. Porcu (2019)
Checkpoint immunologique comme cible thérapeutique
S. Champiat (2015)
Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?
P. Lorigan (2017)
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment
H. El-Osta (2016)
Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
R. Kato (2017)
Immune checkpoint inhibitors side effects and management.
H. Kourie (2016)
Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
Petros Fessas (2019)
Gastrointestinal Tract Adverse Events.
Hamzah Abu-Sbeih (2020)
Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer
Jennifer Dine (2017)
Safety of immune checkpoint inhibitors in Chinese patients with melanoma
X. Wen (2016)
L. Khoja (2015)
Autonomic enteric neuropathy following nivolumab monotherapy in a patient with Lung Cancer
S. Andrews (2020)
Advances in immunotherapy for non-small cell lung cancer.
K. Reckamp (2015)
[Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)].
C. Zhou (2020)
Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Yingying Hu (2020)
Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.
Lei Miao (2017)
Checkpoint inhibitors: outstanding efficacy but at what cost?
J. Klastersky (2016)
Immune Checkpoint Inhibitors-Induced Colitis.
Y. Tian (2018)
Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic.
M. Socinski (2015)
Checkpoint Inhibitors in Nonsmall Cell Lung Cancer
Karen Zeman (2017)See more